NCT00002258View on ClinicalTrials.gov

A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

HIV InfectionsCytopenias

Interventions

DRUG

Interleukin-3

Trial Locations (1)

02215

New England Deaconess Hosp, Boston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sandoz

INDUSTRY